{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:45:47Z","timestamp":1777927547387,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T00:00:00Z","timestamp":1640563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T00:00:00Z","timestamp":1640563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40268-021-00376-x","type":"journal-article","created":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T19:02:32Z","timestamp":1640631752000},"page":"9-13","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Pharmacokinetics and Pharmacodynamics of Ibrexafungerp"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3453-935X","authenticated-orcid":false,"given":"Matthew William","family":"McCarthy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,27]]},"reference":[{"issue":"4","key":"376_CR1","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1093\/jac\/dks466","volume":"68","author":"MA Pfaller","year":"2013","unstructured":"Pfaller MA, Messer SA, Motyl MR, Jones RN, Castanheira M. Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST). J Antimicrob Chemother. 2013;68(4):858\u201363.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"376_CR2","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1517\/13543776.2011.603899","volume":"21","author":"RF Hector","year":"2011","unstructured":"Hector RF, Bierer DE. New \u03b2-glucan inhibitors as antifungal drugs. Expert Opin Ther Pat. 2011;21(10):1597\u2013610.","journal-title":"Expert Opin Ther Pat"},{"issue":"5","key":"376_CR3","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/jac\/40.5.611","volume":"40","author":"DW Denning","year":"1997","unstructured":"Denning DW. Echinocandins and pneumocandins: a new antifungal class with a novel mode of action. J Antimicrob Chemother. 1997;40(5):611\u20134.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"376_CR4","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1128\/JCM.36.10.2950-2956.1998","volume":"36","author":"A Espinel-Ingroff","year":"1998","unstructured":"Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol. 1998;36(10):2950\u20136.","journal-title":"J Clin Microbiol"},{"issue":"Suppl. 3","key":"376_CR5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1439-0507.2002.tb04771.x","volume":"45","author":"OA Cornely","year":"2002","unstructured":"Cornely OA, Schmitz K, Aisenbrey S. The first echinocandin: caspofungin. Mycoses. 2002;45(Suppl. 3):56\u201360.","journal-title":"Mycoses"},{"issue":"9390","key":"376_CR6","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","volume":"362","author":"DW Denning","year":"2003","unstructured":"Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362(9390):1142\u201351.","journal-title":"Lancet"},{"issue":"2","key":"376_CR7","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/cncr.11479","volume":"98","author":"DP Kontoyiannis","year":"2003","unstructured":"Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003;98(2):292\u20139.","journal-title":"Cancer"},{"issue":"3","key":"376_CR8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ijantimicag.2017.09.002","volume":"51","author":"NP Wiederhold","year":"2018","unstructured":"Wiederhold NP. The antifungal arsenal: alternative drugs and future targets. Int J Antimicrob Agents. 2018;51(3):333\u20139.","journal-title":"Int J Antimicrob Agents"},{"key":"376_CR9","doi-asserted-by":"crossref","first-page":"127661","DOI":"10.1016\/j.bmcl.2020.127661","volume":"32","author":"JM Apgar","year":"2021","unstructured":"Apgar JM, Wilkening RR, Parker DL, Meng D, Wildonger KJ, Sperbeck D, et al. Ibrexafungerp: an orally active \u03b2-1,3-glucan synthesis inhibitor. Bioorg Med Chem Lett. 2021;32:127661.","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"376_CR10","doi-asserted-by":"publisher","first-page":"e01989","DOI":"10.1128\/AAC.01989-20","volume":"65","author":"S Chu","year":"2021","unstructured":"Chu S, Long L, McCormick TS, Borroto-Esoda K, Barat S, Ghannoum MA. A second-generation fungerp analog, SCY-247, shows potent in vivo activity in a Murine model of hematogenously disseminated Candida albicans. Antimicrob Agents Chemother. 2021;65(3):e01989-20. https:\/\/doi.org\/10.1128\/AAC.01989-20.","journal-title":"Antimicrob Agents Chemother."},{"key":"376_CR11","doi-asserted-by":"crossref","unstructured":"Jallow S, Govender NP. Ibrexafungerp: a first-in-class oral triterpenoid glucan synthase inhibitor. J Fungi (Basel). 2021;7(3).","DOI":"10.3390\/jof7030163"},{"issue":"12","key":"376_CR12","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s40265-021-01571-5","volume":"81","author":"A Lee","year":"2021","unstructured":"Lee A. Ibrexafungerp: first approval. Drugs. 2021;81(12):1445\u201350.","journal-title":"Drugs"},{"issue":"6","key":"376_CR13","doi-asserted-by":"crossref","first-page":"915.e5","DOI":"10.1016\/j.cmi.2021.02.006","volume":"27","author":"A Mesquida","year":"2021","unstructured":"Mesquida A, Vicente T, Reigadas E, Palomo M, S\u00e1nchez-Carrillo C, Mu\u00f1oz P, et al. In vitro activity of ibrexafungerp and comparators against Candida albicans genotypes from vaginal samples and blood cultures. Clin Microbiol Infect. 2021;27(6):915.e5-8.","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"376_CR14","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/AAC.01588-12","volume":"57","author":"MA Pfaller","year":"2013","unstructured":"Pfaller MA, Messer SA, Motyl MR, Jones RN, Castanheira M. In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. Antimicrob Agents Chemother. 2013;57(2):1065\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"376_CR15","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1128\/AAC.04445-14","volume":"59","author":"AJ Lepak","year":"2015","unstructured":"Lepak AJ, Marchillo K, Andes DR. Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. Antimicrob Agents Chemother. 2015;59(2):1265\u201372.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"376_CR16","doi-asserted-by":"crossref","first-page":"e02068","DOI":"10.1128\/AAC.02068-16","volume":"61","author":"SA Wring","year":"2017","unstructured":"Wring SA, Randolph R, Park S, Abruzzo G, Chen Q, Flattery A, et al. Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis. Antimicrob Agents Chemother. 2017;61(4):e02068-e2116.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"376_CR17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/cpdd.588","volume":"8","author":"S Wring","year":"2019","unstructured":"Wring S, Murphy G, Atiee G, Corr C, Hyman M, Willett M, et al. Clinical pharmacokinetics and drug\u2013drug interaction potential for coadministered SCY-078, an oral fungicidal glucan synthase inhibitor, and tacrolimus. Clin Pharmacol Drug Dev. 2019;8(1):60\u20139.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"10","key":"376_CR18","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/jcph.1146","volume":"58","author":"S Wring","year":"2018","unstructured":"Wring S, Murphy G, Atiee G, Corr C, Hyman M, Willett M, et al. Lack of impact by SCY-078, a first-in-class oral fungicidal glucan synthase inhibitor, on the pharmacokinetics of rosiglitazone, a substrate for CYP450 2C8, supports the low risk for clinically relevant metabolic drug\u2013drug interactions. J Clin Pharmacol. 2018;58(10):1305\u201313.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"376_CR19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-2125.2005.02263.x","volume":"59","author":"MW Hruska","year":"2005","unstructured":"Hruska MW, Amico JA, Langaee TY, Ferrell RE, Fitzgerald SM, Frye RF. The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. Br J Clin Pharmacol. 2005;59(1):70\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"376_CR20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.clpt.2004.05.001","volume":"76","author":"M Niemi","year":"2004","unstructured":"Niemi M, Backman JT, Neuvonen PJ. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin Pharmacol Ther. 2004;76(3):239\u201349.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"376_CR21","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1093\/jac\/dkz277","volume":"74","author":"A Spec","year":"2019","unstructured":"Spec A, Pullman J, Thompson GR, Powderly WG, Tobin EH, Vazquez J, et al. MSG-10: a phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. J Antimicrob Chemother. 2019;74(10):3056\u201362.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"376_CR22","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/13543784.2020.1791820","volume":"29","author":"N Azie","year":"2020","unstructured":"Azie N, Angulo D, Dehn B, Sobel JD. Oral ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis. Expert Opin Investig Drugs. 2020;29(9):893\u2013900.","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"376_CR23","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/14656566.2021.1890026","volume":"22","author":"RE Colombo","year":"2021","unstructured":"Colombo RE, Vazquez JA. An evaluation of ibrexafungerp for the treatment of invasive candidiasis: the evidence to date. Expert Opin Pharmacother. 2021;22(7):797\u2013807.","journal-title":"Expert Opin Pharmacother"},{"key":"376_CR24","doi-asserted-by":"crossref","first-page":"642358","DOI":"10.3389\/fcimb.2021.642358","volume":"11","author":"A Gamal","year":"2021","unstructured":"Gamal A, Chu S, McCormick TS, Borroto-Esoda K, Angulo D, Ghannoum MA. Ibrexafungerp, a novel oral triterpenoid antifungal in development: overview of antifungal activity against. Front Cell Infect Microbiol. 2021;11:642358.","journal-title":"Front Cell Infect Microbiol"},{"issue":"10","key":"376_CR25","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/17512433.2021.1949285","volume":"14","author":"DR Giacobbe","year":"2021","unstructured":"Giacobbe DR, Magnasco L, Sepulcri C, Mikulska M, Koehler P, Cornely OA, et al. Recent advances and future perspectives in the pharmacological treatment of Candida auris infections. Expert Rev Clin Pharmacol. 2021;14(10):1205\u201310.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"376_CR26","doi-asserted-by":"crossref","unstructured":"Seiler GT, Ostrosky-Zeichner L. Investigational agents for the treatment of resistant yeasts and molds. Curr Fungal Infect Rep. 2021:1\u201312.","DOI":"10.1007\/s12281-021-00419-5"},{"issue":"3","key":"376_CR27","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/17476348.2017.1283986","volume":"11","author":"MW McCarthy","year":"2017","unstructured":"McCarthy MW, Aguilar-Zapata D, Petraitis V, Walsh TJ. Diagnosis, classification, and therapeutic interventions for sinopulmonary aspergillosis. Expert Rev Respir Med. 2017;11(3):229\u201338.","journal-title":"Expert Rev Respir Med"},{"issue":"Suppl_3","key":"376_CR28","doi-asserted-by":"crossref","first-page":"S484","DOI":"10.1093\/infdis\/jix103","volume":"216","author":"MW McCarthy","year":"2017","unstructured":"McCarthy MW, Denning DW, Walsh TJ. Future research priorities in fungal resistance. J Infect Dis. 2017;216(Suppl_3):S484\u201392.","journal-title":"J Infect Dis"},{"issue":"Suppl_3","key":"376_CR29","doi-asserted-by":"crossref","first-page":"S474","DOI":"10.1093\/infdis\/jix130","volume":"216","author":"MW McCarthy","year":"2017","unstructured":"McCarthy MW, Kontoyiannis DP, Cornely OA, Perfect JR, Walsh TJ. Novel agents and drug targets to meet the challenges of resistant fungi. J Infect Dis. 2017;216(Suppl_3):S474\u201383.","journal-title":"J Infect Dis"},{"issue":"6","key":"376_CR30","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14787210.2017.1328279","volume":"15","author":"MW McCarthy","year":"2017","unstructured":"McCarthy MW, Walsh TJ. Drug development challenges and strategies to address emerging and resistant fungal pathogens. Expert Rev Anti Infect Ther. 2017;15(6):577\u201384.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"7","key":"376_CR31","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1080\/13543784.2017.1341488","volume":"26","author":"MW McCarthy","year":"2017","unstructured":"McCarthy MW, Walsh TJ. Drugs currently under investigation for the treatment of invasive candidiasis. Expert Opin Investig Drugs. 2017;26(7):825\u201331.","journal-title":"Expert Opin Investig Drugs"},{"issue":"12","key":"376_CR32","first-page":"e01510","volume":"62","author":"M Ghannoum","year":"2019","unstructured":"Ghannoum M, Long L, Isham N, Hager C, Wilson R, Borroto-Esoda K, et al. Activity of a novel 1,3-beta-d-glucan synthase inhibitor, ibrexafungerp (formerly SCY-078), against Candida glabrata. Antimicrob Agents Chemother. 2019;62(12):e01510-e1519.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"376_CR33","doi-asserted-by":"crossref","first-page":"e01692","DOI":"10.1128\/AAC.01692-19","volume":"63","author":"NS Nunnally","year":"2019","unstructured":"Nunnally NS, Etienne KA, Angulo D, Lockhart SR, Berkow EL. Activity of ibrexafungerp, a novel glucan synthase inhibitor against Candida glabrata isolates with FKS mutations. Antimicrob Agents Chemother. 2019;63(11):e01692-e1719.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"376_CR34","doi-asserted-by":"crossref","first-page":"e0056221","DOI":"10.1128\/AAC.00562-21","volume":"65","author":"JD Sobel","year":"2021","unstructured":"Sobel JD, Borroto-Esoda K, Azie N, Angulo D. In vitro pH activity of ibrexafungerp against fluconazole-susceptible and -resistant Candida\u00a0isolates from women with vulvovaginal candidiasis. Antimicrob Agents Chemother. 2021;65(8):e0056221.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"376_CR35","doi-asserted-by":"crossref","first-page":"e02611","DOI":"10.1128\/AAC.02611-18","volume":"63","author":"EL Larkin","year":"2019","unstructured":"Larkin EL, Long L, Isham N, Borroto-Esoda K, Barat S, Angulo D, et al. A novel 1,3-beta-d-glucan inhibitor, ibrexafungerp (formerly SCY-078), shows potent activity in the lower pH environment of vulvovaginitis. Antimicrob Agents Chemother. 2019;63(5):e02611-e2618.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"376_CR36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1348-0421.2008.00083.x","volume":"53","author":"K Satoh","year":"2009","unstructured":"Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53(1):41\u20134.","journal-title":"Microbiol Immunol"},{"issue":"9","key":"376_CR37","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1128\/JCM.00319-11","volume":"49","author":"WG Lee","year":"2011","unstructured":"Lee WG, Shin JH, Uh Y, Kang MG, Kim SH, Park KH, et al. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol. 2011;49(9):3139\u201342.","journal-title":"J Clin Microbiol"},{"issue":"6","key":"376_CR38","doi-asserted-by":"crossref","first-page":"e02694","DOI":"10.1128\/AAC.02694-20","volume":"65","author":"NP Wiederhold","year":"2021","unstructured":"Wiederhold NP, Najvar LK, Olivo M, Morris KN, Patterson HP, Catano G, et al. Ibrexafungerp demonstrates in vitro activity against fluconazole-resistant Candida auris and in vivo efficacy with delayed initiation of therapy in an experimental model of invasive candidiasis. Antimicrob Agents Chemother. 2021;65(6):e02694-e2720.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"376_CR39","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMra1216008","volume":"371","author":"M McCarthy","year":"2014","unstructured":"McCarthy M, Rosengart A, Schuetz AN, Kontoyiannis DP, Walsh TJ. Mold infections of the central nervous system. N Engl J Med. 2014;371(2):150\u201360.","journal-title":"N Engl J Med"},{"key":"376_CR40","doi-asserted-by":"crossref","first-page":"i5978","DOI":"10.1136\/bmj.i5978","volume":"355","author":"M McCarthy","year":"2016","unstructured":"McCarthy M. Hospital transmitted Candida auris infections confirmed in the US. BMJ. 2016;355:i5978.","journal-title":"BMJ"},{"issue":"6","key":"376_CR41","doi-asserted-by":"crossref","first-page":"e02429","DOI":"10.1128\/AAC.02429-19","volume":"64","author":"V Petraitis","year":"2020","unstructured":"Petraitis V, Petraitiene R, Katragkou A, Maung BBW, Naing E, Kavaliauskas P, et al. Combination therapy with ibrexafungerp (formerly SCY-078), a first-in-class triterpenoid inhibitor of (1\u21923)-\u03b2-d-glucan synthesis, and isavuconazole for treatment of experimental invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2020;64(6):e02429-e2519.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"376_CR42","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3390\/jof6040198","volume":"6","author":"TJ Walsh","year":"2020","unstructured":"Walsh TJ, Petraitiene R, Petraitis V. Modeling invasive aspergillosis: how close are predicted antifungal targets? J Fungi (Basel). 2020;6(4):198.","journal-title":"J Fungi (Basel)."},{"issue":"11","key":"376_CR43","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1128\/AAC.03261-14","volume":"58","author":"A Katragkou","year":"2014","unstructured":"Katragkou A, McCarthy M, Meletiadis J, Petraitis V, Moradi PW, Strauss GE, et al. In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds. Antimicrob Agents Chemother. 2014;58(11):6934\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"376_CR44","first-page":"e172","volume":"24","author":"G Quind\u00f3s","year":"2019","unstructured":"Quind\u00f3s G, Gil-Alonso S, Marcos-Arias C, Sevillano E, Mateo E, Jauregizar N, et al. Therapeutic tools for oral candidiasis: current and new antifungal drugs. Med Oral Patol Oral Cir Bucal. 2019;24(2):e172\u201380.","journal-title":"Med Oral Patol Oral Cir Bucal"},{"issue":"2","key":"376_CR45","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.mycmed.2018.03.002","volume":"28","author":"J Kr\u00f3l","year":"2018","unstructured":"Kr\u00f3l J, Nawrot U, Bartoszewicz M. Anti-candidal activity of selected analgesic drugs used alone and in combination with fluconazole, itraconazole, voriconazole, posaconazole and isavuconazole. J Mycol Med. 2018;28(2):327\u201331.","journal-title":"J Mycol Med."},{"issue":"5","key":"376_CR46","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s11046-021-00560-2","volume":"186","author":"G Waterer","year":"2021","unstructured":"Waterer G. Advances in anti-fungal therapies. Mycopathologia. 2021;186(5):665\u201372.","journal-title":"Mycopathologia"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-021-00376-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-021-00376-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-021-00376-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T09:27:53Z","timestamp":1646040473000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-021-00376-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,27]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["376"],"URL":"https:\/\/doi.org\/10.1007\/s40268-021-00376-x","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,27]]},"assertion":[{"value":"5 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. McCarthy has nothing to declare and reports no conflicts of interests associated with this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}